Pharma BD Deal Intelligence
An option structure vindicated: AbbVie's cautious $6 million upfront bet on Aldeyra's reproxalap — with $100 million and $300 million in milestones contingent on approval — proved out its risk-transfer design when the dry-eye program drew three separate FDA Complete Response Letters.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie and Aldeyra Therapeutics today announced they have entered into an exclusive option agreement for reproxalap. Upon exercise, Aldeyra would receive…
Aldeyra Therapeutics shares fell more than 30 percent after the company announced an option deal with AbbVie for dry-eye candidate reproxalap that investors…
FDA rejected Aldeyra's reproxalap for dry eye disease for the third time, citing inconsistent study findings and a lack of adequate and well-controlled…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Aldeyra and AbbVie entered an exclusive option agreement for reproxalap (a reactive aldehyde species modulator) on October 31, 2023. Upon option exercise, AbbVie would pay $100M upfront (less $6M in prior option fees) for a co-exclusive U.S. license plus an exclusive ex-U.S. license, with Aldeyra eligible for up to $300M in regulatory/commercial milestones, a 60/40 U.S. profit share to AbbVie, and tiered ex-U.S. royalties. The parties EXPANDED the agreement on November 18, 2024 (concurrent with FDA acceptance of the dry-eye NDA): they added pre-commercial cost-sharing (60% AbbVie / 40% Aldeyra), a $100M milestone contingent on FDA approval, and amended the option to expire 10 business days following any FDA approval of reproxalap for dry eye disease. The deal's economics never triggered: the reproxalap dry-eye program drew three Complete Response Letters (November 2023, April 2025, and a third on March 17, 2026 citing a lack of substantial evidence of efficacy, which sent Aldeyra shares down ~65% and spawned securities class actions). As of Aldeyra's February 27, 2026 10-K and its March 2026 8-K, AbbVie had NOT exercised the option and had NOT terminated the agreement; exercise remains contingent on an FDA approval that has not occurred, leaving the deal pending and increasingly imperiled.
16.4M US cases/yr · $3.5B US branded dry eye disease prescription market 2023 (USD MM) · 400 Total deal size (USD MM $100M upfront + $300M milestones)
Dry eye disease (DED) affects approximately 16.4 million US adults diagnosed (Farrand et al., Am J Ophthalmol 2017) with a broader symptomatic population estimated at 38 million and growing on digital device use and aging demographics. Allergic conjunctivitis affects an estimated 40 million Americans seasonally. The DED therapeutic market is dominated by Restasis (cyclosporine, now generic), Xiidra (lifitegrast, Novartis), Cequa (cyclosporine 0.09%, Sun Pharma), Tyrvaya (varenicline nasal spray, Viatris/Oyster Point), Miebo (perfluorohexyloctane, Bausch + Lomb/Novaliq, approved May 2023), and Vevye (cyclosporine 0.1%, Harrow/Novaliq, approved May 2023). 2023 combined US DED branded prescription market exceeded $3.5 billion with substantial seasonal co-promotion overlap with allergic conjunctivitis products (Pataday, Zerviate, Lastacaft). Reproxalap, an ocular solution that covalently traps reactive aldehyde species (RASP) linked to ocular surface inflammation, would be the first agent in its mechanistic class if approved. The FDA issued a Complete Response Letter in November 2023 citing insufficient signs and symptoms efficacy data, and a second CRL in April 2025, complicating the AbbVie option structure. Allergic conjunctivitis remains an undifferentiated expansion indication.
The dry eye disease competitive landscape is crowded and mechanistically diverse, and reproxalap (RASP inhibitor) would enter as a novel mechanism. Approved US DED therapies: cyclosporine 0.05% (Restasis, AbbVie/Allergan) now genericized; lifitegrast (Xiidra, Novartis) LFA-1/ICAM-1 inhibitor; cyclosporine 0.09% (Cequa, Sun Pharma) and cyclosporine 0.1% (Vevye, Harrow/Novaliq); varenicline nasal spray (Tyrvaya, Viatris) alpha-4-beta-2 nicotinic agonist; perfluorohexyloctane (Miebo, Bausch + Lomb) evaporation modulator approved May 2023; loteprednol 0.25% (Eysuvis, Alcon) short-term steroid. Approved allergic conjunctivitis therapies: olopatadine (Pataday, Alcon), cetirizine (Zerviate, Harrow), alcaftadine (Lastacaft, Allergan). Late-stage DED pipeline competitors to reproxalap: RGN-259 (ReGenTree/GtreeBNT thymosin beta-4), tivanisiran (Sylentis siRNA), lotilaner (Xdemvy, Tarsus - approved July 2023 for Demodex blepharitis with adjacent DED potential), and CBT-001 (Cloudbreak nintedanib for pterygium). AbbVie's strategic rationale is to defend the Allergan ophthalmology portfolio post-Restasis loss of exclusivity with a differentiated novel-MOA entrant; the deal's option structure preserves AbbVie flexibility pending FDA resolution.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Aldeyra Therapeutics, Inc. (this deal) | 2023 | $400M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2023 deals · AbbVie Inc. deals · Immunology deals